Respiratory - Wiki-CORONA

Symbols	Name 1	Name 2	Pathways 1 Hide	Pathways 2 Hide	Drugs 1 Hide	Drugs 2 Hide	Diseases 1 Hide	Diseases 2 Hide
APP and YWHAZ	amyloid beta precursor protein	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1 activates NFkB by phosphorylation and activation of IKKs complex The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation	Activation of BAD and translocation to mitochondria Translocation of SLC2A4 (GLUT4) to the plasma membrane Deactivation of the beta-catenin transactivating complex Rap1 signalling GP1b-IX-V activation signalling KSRP (KHSRP) binds and destabilizes mRNA Interleukin-3, Interleukin-5 and GM-CSF signaling RHO GTPases activate PKNs TP53 Regulates Metabolic Genes Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex NOTCH4 Activation and Transmission of Signal to the Nucleus Negative regulation of NOTCH4 signaling Regulation of localization of FOXO transcription factors	Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Phenserine Tiomolibdate ion CAD106 Mito-4509 Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F)	Phenethyl Isothiocyanate	Alzheimer's disease (AD)
APP and CAMK1D	amyloid beta precursor protein	calcium/calmodulin dependent protein kinase ID	Platelet degranulation ECM proteoglycans Regulation of Insulin-like Growth Factor (IGF) transport and uptake by Insulin-like Growth Factor Binding Proteins (IGFBPs) G alpha (q) signalling events G alpha (i) signalling events Lysosome Vesicle Biogenesis Formyl peptide receptors bind formyl peptides and many other ligands TAK1 activates NFkB by phosphorylation and activation of IKKs complex The NLRP3 inflammasome Advanced glycosylation endproduct receptor signaling Advanced glycosylation endproduct receptor signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models Post-translational protein phosphorylation TRAF6 mediated NF-kB activation Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Insertion of tail-anchored proteins into the endoplasmic reticulum membrane Purinergic signaling in leishmaniasis infection Amyloid fiber formation		Deferoxamine Aluminium Zinc L-methionine (R)-S-oxide Resveratrol Phenserine Tiomolibdate ion CAD106 Mito-4509 Dimercaprol Copper Florbetaben (18F) Florbetapir (18F) Flutemetamol (18F)	N-(5-METHYL-1H-PYRAZOL-3-YL)-2-PHENYLQUINAZOLIN-4-AMINE	Alzheimer's disease (AD)
FASLG and NCF1	Fas ligand	neutrophil cytosolic factor 1	Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited Interleukin-4 and Interleukin-13 signaling Dimerization of procaspase-8 FasL/ CD95L signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models FOXO-mediated transcription of cell death genes TNFs bind their physiological receptors	ROS and RNS production in phagocytes Cross-presentation of particulate exogenous antigens (phagosomes) Detoxification of Reactive Oxygen Species VEGFA-VEGFR2 Pathway RHO GTPases Activate NADPH Oxidases		Dextromethorphan	Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS	Chronic granulomatous disease, including the following four diseases: X-linked CGD (gp91 phox CGD); p22phox deficiency (p22phox CGD); p47phox deficiency (p47phox CGD); p67phox deficiency (p67phox CGD)
FASLG and HCK	Fas ligand	HCK proto-oncogene, Src family tyrosine kinase	Caspase activation via Death Receptors in the presence of ligand Regulation by c-FLIP RIPK1-mediated regulated necrosis CASP8 activity is inhibited Interleukin-4 and Interleukin-13 signaling Dimerization of procaspase-8 FasL/ CD95L signaling Deregulated CDK5 triggers multiple neurodegenerative pathways in Alzheimer's disease models FOXO-mediated transcription of cell death genes TNFs bind their physiological receptors	Nef and signal transduction FCGR activation Regulation of signaling by CBL Regulation of signaling by CBL FLT3 Signaling FCGR3A-mediated IL10 synthesis FCGR3A-mediated phagocytosis		1-Ter-Butyl-3-P-Tolyl-1h-Pyrazolo[3,4-D]Pyrimidin-4-Ylamine Phosphonotyrosine Quercetin Bosutinib	Autoimmune lymphoproliferative syndromes (ALPS), including the following five diseases: CD95 (Fas) defect, ALPS type 1a; CD95L (Fas ligand) defect, ALPS type 1b; Caspase 10 defect, ALPS type 2a; Caspase 8 defext, ALPS type 2b; Activaing N-Ras defect, N-Ras ALPS
AQP1 and LMNA	aquaporin 1 (Colton blood group)	lamin A/C	Erythrocytes take up carbon dioxide and release oxygen Erythrocytes take up oxygen and release carbon dioxide Vasopressin regulates renal water homeostasis via Aquaporins Passive transport by Aquaporins	XBP1(S) activates chaperone genes Signaling by BRAF and RAF fusions	Acetazolamide			Restrictive dermopathy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Mandibuloacral dysplasia Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy Limb-girdle muscular dystrophy (LGMD) Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Hutchinson-Gilford progeria syndrome
AQP3 and LMNA	aquaporin 3 (Gill blood group)	lamin A/C	Vasopressin regulates renal water homeostasis via Aquaporins Passive transport by Aquaporins	XBP1(S) activates chaperone genes Signaling by BRAF and RAF fusions				Restrictive dermopathy Emery-Dreifuss muscular dystrophy Dilated cardiomyopathy (DCM) Charcot-Marie-Tooth disease (CMT); Hereditary motor and sensory neuropathy; Peroneal muscular atrophy Mandibuloacral dysplasia Congenital muscular dystrophies (CMD/MDC), including: Merosin-deficient CMD (MDC1A); Ullrich CMD (UCMD); Integrin alpha7-deficient CMD; CMD with joint hyperlaxity (CMDH); CMD with epidermolysis bullosa; Walker-Warburg syndrome (WWS); Muscle-eye-brain disease (MEB); Fukuyama CMD (FCMD); CMD with muscle hypertrophy (MDC1C); CMD with severe intellectual impairment and abnormal glycosylation (MDC1D); Rigid spine syndrome (RSS); LMNA-deficient CMD; CMD with respiratory failure and muscle hypertrophy (MDC1B); Bethlem myopathy Limb-girdle muscular dystrophy (LGMD) Familial partial lipodystrophy (FPL), including the following four diseases: Kobberling-type lipodystrophy (FPLD1); Dunnigan-type lipodystrophy (FPLD2); Dunnigan-like lipodystrophy (FPLD3); AKT2 associated lipodystrophy Hutchinson-Gilford progeria syndrome
AR and FOXA1	androgen receptor	forkhead box A1	HSP90 chaperone cycle for steroid hormone receptors (SHR) Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 Ub-specific processing proteases RUNX2 regulates osteoblast differentiation RUNX2 regulates osteoblast differentiation	Estrogen-dependent gene expression	Diethylstilbestrol Levonorgestrel Progesterone Spironolactone Flutamide Oxandrolone Fluphenazine Testosterone Mitotane Estrone Nilutamide Tamoxifen Fludrocortisone Drostanolone Norgestimate Nandrolone phenpropionate Ketoconazole Acetophenazine Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Oxybenzone Delta1-dihydrotestosterone Boldenone Calusterone Propericiazine Prasterone Flufenamic Acid Dihydrotestosterone (R)-Bicalutamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone acetate LGD2941 Oxymetholone Methyltestosterone Norelgestromin 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Triclosan Nandrolone decanoate Ulipristal Enzalutamide Eugenol Dienogest Norgestrel Homosalate Enzacamene Esculin		46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS) 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism Prostate cancer Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease
AR and MYBBP1A	androgen receptor	MYB binding protein 1a	HSP90 chaperone cycle for steroid hormone receptors (SHR) Nuclear Receptor transcription pathway SUMOylation of intracellular receptors Activated PKN1 stimulates transcription of AR (androgen receptor) regulated genes KLK2 and KLK3 Ub-specific processing proteases RUNX2 regulates osteoblast differentiation RUNX2 regulates osteoblast differentiation	B-WICH complex positively regulates rRNA expression	Diethylstilbestrol Levonorgestrel Progesterone Spironolactone Flutamide Oxandrolone Fluphenazine Testosterone Mitotane Estrone Nilutamide Tamoxifen Fludrocortisone Drostanolone Norgestimate Nandrolone phenpropionate Ketoconazole Acetophenazine Bicalutamide Fluoxymesterone Drospirenone Danazol Testosterone Propionate Oxybenzone Delta1-dihydrotestosterone Boldenone Calusterone Propericiazine Prasterone Flufenamic Acid Dihydrotestosterone (R)-Bicalutamide Methyltrienolone (3AALPHA,4ALPHA,7ALPHA,7AALPHA)- 3A,4,7,7A-TETRAHYDRO-2-(4-NITRO-1-NAPHTHALENYL)-4,7-ETHANO-1H-ISOINDOLE-1,3(2H)-DIONE Cyproterone acetate LGD2941 Oxymetholone Methyltestosterone Norelgestromin 17-HYDROXY-18A-HOMO-19-NOR-17ALPHA-PREGNA-4,9,11-TRIEN-3-ONE (2S)-N-(4-cyano-3-iodophenyl)-3-(4-cyanophenoxy)-2-hydroxy-2-methylpropanamide 2-CHLORO-4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-3-METHYLBENZONITRILE (2S)-3-(4-chloro-3-fluorophenoxy)-N-[4-cyano-3-(trifluoromethyl)phenyl]-2-hydroxy-2-methylpropanamide 4-{[(1R,2S)-1,2-dihydroxy-2-methyl-3-(4-nitrophenoxy)propyl]amino}-2-(trifluoromethyl)benzonitrile (2S)-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]-3-(pentafluorophenoxy)propanamide (2S)-3-[4-(acetylamino)phenoxy]-2-hydroxy-2-methyl-N-[4-nitro-3-(trifluoromethyl)phenyl]propanamide (R)-3-BROMO-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE (5S,8R,9S,10S,13R,14S,17S)-13-{2-[(3,5-DIFLUOROBENZYL)OXY]ETHYL}-17-HYDROXY-10-METHYLHEXADECAHYDRO-3H-CYCLOPENTA[A]PHENANTHREN-3-ONE S-3-(4-FLUOROPHENOXY)-2-HYDROXY-2-METHYL-N-[4-NITRO-3-(TRIFLUOROMETHYL)PHENYL]PROPANAMIDE 1-TERT-BUTYL-3-(2,5-DIMETHYLBENZYL)-1H-PYRAZOLO[3,4-D]PYRIMIDIN-4-AMINE 4-[(7R,7AS)-7-HYDROXY-1,3-DIOXOTETRAHYDRO-1H-PYRROLO[1,2-C]IMIDAZOL-2(3H)-YL]-1-NAPHTHONITRILE 2-chloro-4-{[(1R,3Z,7S,7aS)-7-hydroxy-1-(trifluoromethyl)tetrahydro-1H-pyrrolo[1,2-c][1,3]oxazol-3-ylidene]amino}-3-methylbenzonitrile 6-[BIS(2,2,2-TRIFLUOROETHYL)AMINO]-4-(TRIFLUOROMETHYL)QUINOLIN-2(1H)-ONE 3-[(4-AMINO-1-TERT-BUTYL-1H-PYRAZOLO[3,4-D]PYRIMIDIN-3-YL)METHYL]PHENOL Triclosan Nandrolone decanoate Ulipristal Enzalutamide Eugenol Dienogest Norgestrel Homosalate Enzacamene Esculin		46,XY disorders of sex development (Disorders in androgen synthesis or action), including: Congenital adrenal hyperplasias; Leydig cell hypoplasia; Androgen insensitivity syndrome (AIS) 46,XY disorders of sex development (Other), including: Persistent Mullerian duct syndrome; Hypospadias; Cryptorchidism Prostate cancer Spinal and bulbar muscular atrophy (SBMA); Kennedy's disease
ARAF and YWHAZ	A-Raf proto-oncogene, serine/threonine kinase	tyrosine 3-monooxygenase/tryptophan 5-monooxygenase activation protein zeta	RAF activation MAP2K and MAPK activation Negative regulation of MAPK pathway Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Signaling downstream of RAS mutants	Activation of BAD and translocation to mitochondria Translocation of SLC2A4 (GLUT4) to the plasma membrane Deactivation of the beta-catenin transactivating complex Rap1 signalling GP1b-IX-V activation signalling KSRP (KHSRP) binds and destabilizes mRNA Interleukin-3, Interleukin-5 and GM-CSF signaling RHO GTPases activate PKNs TP53 Regulates Metabolic Genes Chk1/Chk2(Cds1) mediated inactivation of Cyclin B:Cdk1 complex NOTCH4 Activation and Transmission of Signal to the Nucleus Negative regulation of NOTCH4 signaling Regulation of localization of FOXO transcription factors	ATP	Phenethyl Isothiocyanate	Noonan syndrome and related disorders, including: Noonan syndrome (NS); Leopard syndrome (LS); Noonan syndrome-like with loose anagen hair (NS/LAH); CBL-mutation associated syndrome (CBL); Neurofibromatosis type 1 (NF1); Neurofibromatosis type 2 (NF2); Neurofibromatosis-Noonan syndrome (NFNS); Legius syndrome; Cardiofaciocutaneous syndrome (CFCS); Costello syndrome (CS)
TRIM23 and TSHZ3	tripartite motif containing 23	teashirt zinc finger homeobox 3
TRIM23 and ATPAF2	tripartite motif containing 23	ATP synthase mitochondrial F1 complex assembly factor 2
ARF1 and INSR	ADP ribosylation factor 1	insulin receptor	Synthesis of PIPs at the plasma membrane Synthesis of PIPs at the Golgi membrane Nef Mediated CD4 Down-regulation trans-Golgi Network Vesicle Budding MHC class II antigen presentation Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis COPI-mediated anterograde transport COPI-dependent Golgi-to-ER retrograde traffic Intra-Golgi traffic Gene and protein expression by JAK-STAT signaling after Interleukin-12 stimulation	PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling IRS activation Signal attenuation Insulin receptor signalling cascade Signaling by Insulin receptor Insulin receptor recycling	1,3-Propandiol Guanosine-3'-Monophosphate-5'-Diphosphate Guanosine-5'-Triphosphate Guanosine-5'-Diphosphate Brefeldin A Myristic acid Glycerin	Insulin Human Insulin Lispro Insulin Glargine Insulin Pork Mecasermin Insulin Aspart Insulin Detemir Insulin Glulisine Adenosine-5'-[Beta, Gamma-Methylene]Triphosphate NN344 AT1391 [4-({5-(AMINOCARBONYL)-4-[(3-METHYLPHENYL)AMINO]PYRIMIDIN-2-YL}AMINO)PHENYL]ACETIC ACID Chromic chloride Insulin Degludec Brigatinib		Rabson-Mendenhall syndrome Leprechaunism ; Donohue syndrome
ARL4D and PGAM1	ADP ribosylation factor like GTPase 4D	phosphoglycerate mutase 1		Neutrophil degranulation Glycolysis Gluconeogenesis		Copper
ARF6 and ALDH5A1	ADP ribosylation factor 6	aldehyde dehydrogenase 5 family member A1	TBC/RABGAPs Clathrin-mediated endocytosis MET receptor recycling	Degradation of GABA	5'-Guanosine-Diphosphate-Monothiophosphate Guanosine-5'-Diphosphate Myristic acid	Succinic acid NADH Valproic Acid Chlormerodrin		Succinic semialdehyde dehydrogenase (SSADH) deficiency; 4-Hydroxybutyric aciduria (4-HBA)
ARF6 and ARRB1	ADP ribosylation factor 6	arrestin beta 1	TBC/RABGAPs Clathrin-mediated endocytosis MET receptor recycling	Activated NOTCH1 Transmits Signal to the Nucleus G alpha (s) signalling events Lysosome Vesicle Biogenesis Golgi Associated Vesicle Biogenesis Thrombin signalling through proteinase activated receptors (PARs) Activation of SMO Activation of SMO MAP2K and MAPK activation Ub-specific processing proteases Signaling by moderate kinase activity BRAF mutants Signaling by high-kinase activity BRAF mutants Signaling by BRAF and RAF fusions Paradoxical activation of RAF signaling by kinase inactive BRAF Cargo recognition for clathrin-mediated endocytosis Clathrin-mediated endocytosis Signaling downstream of RAS mutants	5'-Guanosine-Diphosphate-Monothiophosphate Guanosine-5'-Diphosphate Myristic acid
RHOA and BCR	ras homolog family member A	BCR activator of RhoGEF and GTPase	GPVI-mediated activation cascade Axonal growth inhibition (RHOA activation) Rho GTPase cycle PI3K/AKT activation Axonal growth stimulation TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) TGF-beta receptor signaling in EMT (epithelial to mesenchymal transition) G beta:gamma signalling through PI3Kgamma EPHB-mediated forward signaling EPHB-mediated forward signaling EPHA-mediated growth cone collapse EPHA-mediated growth cone collapse PCP/CE pathway G alpha (12/13) signalling events Sema4D mediated inhibition of cell attachment and migration Sema4D induced cell migration and growth-cone collapse Sema4D induced cell migration and growth-cone collapse VEGFA-VEGFR2 Pathway RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases Activate ROCKs RHO GTPases Activate ROCKs RHO GTPases Activate Formins RHO GTPases Activate Rhotekin and Rhophilins RHO GTPases Activate Rhotekin and Rhophilins Ovarian tumor domain proteases ERBB2 Regulates Cell Motility Neutrophil degranulation PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases SLIT2:ROBO1 increases RHOA activity	Signaling by cytosolic FGFR1 fusion mutants Rho GTPase cycle Signaling by FGFR1 in disease	Guanosine-5'-Diphosphate	Dasatinib Bosutinib Ponatinib		Chronic myeloid leukemia (CML) Acute lymphoblastic leukemia (ALL) (precursor B lymphoblastic leukemia)
ARHGAP1 and RAC1	Rho GTPase activating protein 1	Rac family small GTPase 1	Rho GTPase cycle	GPVI-mediated activation cascade PIP3 activates AKT signaling Signaling by SCF-KIT Translocation of SLC2A4 (GLUT4) to the plasma membrane Nef and signal transduction NRAGE signals death through JNK Rho GTPase cycle Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling FCERI mediated MAPK activation DSCAM interactions CD28 dependent Vav1 pathway EPHB-mediated forward signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion PCP/CE pathway Sema4D mediated inhibition of cell attachment and migration DCC mediated attractive signaling DCC mediated attractive signaling Activation of RAC1 Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Signal transduction by L1 VEGFR2 mediated vascular permeability RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins RHO GTPases Activate NADPH Oxidases MAPK6/MAPK4 signaling Neutrophil degranulation PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAP1 and RAC1 NTRK2 activates RAC1 Activated NTRK2 signals through CDK5 Activation of RAC1 downstream of NMDARs FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis WNT5:FZD7-mediated leishmania damping Factors involved in megakaryocyte development and platelet production		Dextromethorphan Azathioprine Guanosine-5'-Diphosphate
ARHGDIA and RAC2	Rho GDP dissociation inhibitor alpha	Rac family small GTPase 2	Axonal growth inhibition (RHOA activation) Rho GTPase cycle Axonal growth stimulation	GPVI-mediated activation cascade ROS and RNS production in phagocytes PIP3 activates AKT signaling Rho GTPase cycle Constitutive Signaling by Aberrant PI3K in Cancer PCP/CE pathway RHO GTPases Activate NADPH Oxidases PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling		Dextromethorphan		Leukocyte adhesion deficiency (LAD), including the following four diseases: Leukocyte adhesion deficiency (I); Leukocyte adhesion deficiency (II); Leukocyte adhesion deficiency (III); LAD with Rac2 deficiency
ARHGDIA and RAC1	Rho GDP dissociation inhibitor alpha	Rac family small GTPase 1	Axonal growth inhibition (RHOA activation) Rho GTPase cycle Axonal growth stimulation	GPVI-mediated activation cascade PIP3 activates AKT signaling Signaling by SCF-KIT Translocation of SLC2A4 (GLUT4) to the plasma membrane Nef and signal transduction NRAGE signals death through JNK Rho GTPase cycle Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling FCERI mediated MAPK activation DSCAM interactions CD28 dependent Vav1 pathway EPHB-mediated forward signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion PCP/CE pathway Sema4D mediated inhibition of cell attachment and migration DCC mediated attractive signaling DCC mediated attractive signaling Activation of RAC1 Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Signal transduction by L1 VEGFR2 mediated vascular permeability RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins RHO GTPases Activate NADPH Oxidases MAPK6/MAPK4 signaling Neutrophil degranulation PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAP1 and RAC1 NTRK2 activates RAC1 Activated NTRK2 signals through CDK5 Activation of RAC1 downstream of NMDARs FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis WNT5:FZD7-mediated leishmania damping Factors involved in megakaryocyte development and platelet production		Dextromethorphan Azathioprine Guanosine-5'-Diphosphate
ARHGDIB and RAC1	Rho GDP dissociation inhibitor beta	Rac family small GTPase 1	Rho GTPase cycle	GPVI-mediated activation cascade PIP3 activates AKT signaling Signaling by SCF-KIT Translocation of SLC2A4 (GLUT4) to the plasma membrane Nef and signal transduction NRAGE signals death through JNK Rho GTPase cycle Regulation of actin dynamics for phagocytic cup formation Regulation of actin dynamics for phagocytic cup formation Constitutive Signaling by Aberrant PI3K in Cancer DAP12 signaling FCERI mediated MAPK activation DSCAM interactions CD28 dependent Vav1 pathway EPHB-mediated forward signaling Ephrin signaling EPH-ephrin mediated repulsion of cells Sema3A PAK dependent Axon repulsion SEMA3A-Plexin repulsion signaling by inhibiting Integrin adhesion PCP/CE pathway Sema4D mediated inhibition of cell attachment and migration DCC mediated attractive signaling DCC mediated attractive signaling Activation of RAC1 Inactivation of CDC42 and RAC1 VEGFA-VEGFR2 Pathway Signal transduction by L1 VEGFR2 mediated vascular permeability RHO GTPases activate PKNs RHO GTPases activate CIT RHO GTPases activate CIT RHO GTPases activate KTN1 RHO GTPases activate IQGAPs RHO GTPases activate PAKs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate WASPs and WAVEs RHO GTPases Activate Formins RHO GTPases Activate Formins RHO GTPases Activate NADPH Oxidases MAPK6/MAPK4 signaling Neutrophil degranulation PI5P, PP2A and IER3 Regulate PI3K/AKT Signaling PTK6 Regulates RHO GTPases, RAS GTPase and MAP kinases MET activates RAP1 and RAC1 NTRK2 activates RAC1 Activated NTRK2 signals through CDK5 Activation of RAC1 downstream of NMDARs FCGR3A-mediated phagocytosis FCGR3A-mediated phagocytosis WNT5:FZD7-mediated leishmania damping Factors involved in megakaryocyte development and platelet production		Dextromethorphan Azathioprine Guanosine-5'-Diphosphate

Search Results for: Respiratory